Eli Lilly's Core Product Trends For The Week Ending 9/24

Citigroup has published a research report for Eli Lilly LLY reporting on core product trends for the week ending on 9/24. In the report, Citigroup writes " Effient: 2.7% NRx's of Plavix Market; We Assume 2010 US Sales of $100M. Effient weekly NRx/TRx of 5,691 (+3% seq.)/13,578(+2%) vs.Plavix at 203,096 (+3%) /665,533(+1%). Effient is flat priced at $5.40/day (at a modest premium to Plavix [$5.38/day] after BMY/SNY took a 4.9% price increase in Sept '10).  Livalo: Quarter to date TRx/NRx was 16.9k/14.3k; TRx share in the week was 0.06%.Livalo 1/2/3mg are flat price at $3.27/day,a discount to branded statins.  Cymbalta: $2.2B Annual Run Rate Implied by 4-Wk Avg. TRx's. Our model assumes 2010 US sales of $2.7B (+7%). Cymbalta posted weekley NRx/TRx of 159,393(+1%)/366,820(-0%); 9.8%(-3bp) TRx share of the depression market. Rolling 4week/12week NRx growth rates were +0%/+2%; TRx growth rates were +1%/+0%.LLY took a 8% Cymbalta PI on 9/3/10, w/ 30mg/60mg flat priced at $4.61/day. FDA action on chronic pain sNDA expected in 4Q10.  Zyprexa: 10.7%(-3bp)TRx Share of Antipsychotic Mkt. We assume ‘10 US sales of $2.4B. Zyprexa posted weekly NRx/TRx of 50,779(-1%)/113,979(-1%). Rolling 4wk/12wk NRx growth rates were -3%/-2% & TRx growth rates were - 1%/-2%. Zyprexa is priced at a WAC of $7.82(2.5mg/day) to$27.80(20mg/day) after an 8% PI on 3/2/10. FDA approved Zyprexa Relprevv 12/14/09; VNDA's Fanapt launched 1/11 at $17.33/day; MRK's Saphris on 10/19 at $16.34 / day.  Byetta: ~$510M Annual Run Rate Implied by 4-Wk Avg. TRx's Vs. Our Model Which Assumes '10 US Sales of $607M. Byetta posted weekly NRx/TRx of 17,723 (+2%)/45,685 (-2%). Rolling 4wk/12wk NRx growth was -24%/-18% & TRx growth rates were -25%/-24%. Byetta is priced at WAC of $219.39/ $257.20 for 5/10mcg pens after an 8% PI on the 10mcg pen. LLY/AMLN's PDUFA for Bydureon (exenatide once weekly) is 10/22/2010. Bydureon is expected to carry a new/separate label from Byetta with DURATION 1 & 2 data & a price premium to NVO's Victoza. NVO's Victoza is expanding the GLP-1 mkt w/ NRx/TRx of 11,720(-3%)/21,730(-2%) & NRx/TRx share of 39.8%/32.2%. Victoza18mg/3ml 2&3 pack pens are priced at $238.39&$357.59, respectively.  Humalog: 42.9% (-16bp) TRx Share of Fast-Acting Insulin Analogs; Humulin: 56.4%(-18bp) TRx Share of Human Insulins. Our model assumes '10 US sales of $1.3B(+5%)/$440M(+10%) for Humalog/Humulin. Humalog posted weekly NRx/TRx of 58,161(+0%)/147,329(-2%). Humulin posted weekly NRx/TRx of 38,713(-1%)/103,688(-3%). Rolling 4wk/12wk NRx growth rates were +3%/+4% for Humalog and -6%/-3% for Humulin. LLY's insulin franchise represents ~14% of‘10-13 incremental adj. sales. Humalog-KWIK/Humulin 5x3 ml pens are flat priced at a WAC of $205.77 / $154.58, respectively." Citigroup maintains its Buy rating and $41 price target. Eli Lilly closed yesterday at $36.89. Don't miss these trading ideas!
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsbyettaCitigroupcymbaltaeffienteli lillyhumaloglivalozyprexa
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!